No Data
AVIC Securities: Pharmaceutical industry performance under pressure in the third quarter, total market value of heavyweight in fund holdings increased.
The demand for blood sector in biological products remains high, with vaccines facing sales pressure due to factors such as previous market consumption; active pharmaceutical ingredients are entering the tail end of downstream inventory, showing an improvement in demand, and future performance is expected to gradually improve.
Express News | Aier Eye Hospital Group: 6.4171 million shares of stock-based incentive restricted shares will be lifted on November 6.
Earnings Miss: Aier Eye Hospital Group Co., Ltd. Missed EPS By 9.1% And Analysts Are Revising Their Forecasts
Aier Eye Hospital Group (300015): Possessing operational resilience, waiting quietly for consumer recovery.
Subject: The company released its third quarter report for 2024, with revenue of 16.302 billion yuan in 24Q1-Q3, a year-on-year increase of 1.58%, net income attributable to shareholders of 3.452 billion yuan, a year-on-year increase of 8.5%, and non-net income attributable to shareholders of 31.13.
Aier Eye Hospital Group (300015): Short-term growth under pressure, hospital acquisitions continue to proceed in an orderly manner.
Affected by the macroeconomic environment, the third quarter saw a year-on-year decline in revenue and profits. In 2024Q3, the company achieved revenue of 5.756 billion yuan, a decrease of 0.68% year-on-year; net income attributable to shareholders was 1.402 billion yuan, a decrease of 4.
Aier Eye Hospital's Q3 Profit Falls 5%, Revenue Shrinks 1%
No Data
No Data